Mood Disorders
Methodology & AI Transparency ⓘ
Mood Disorders Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Most people feel sad or irritable from time to time.
- 2 Real-world patient consensus: Mapped to Depression, Bipolar & Mood Disorders under ICD-10-CM F32.2 for Mood Disorders clinical workups.
- 3 Typical cash cost range: Primary evaluation for Mood Disorders incorporates structured psychiatric history [Mood Disorders F32.2] and symptom diary review.
- 4 Top reported side effects / signs: Key Depression & Mood biomarkers for Mood Disorders (F32.2): TSH & Free in Mood Disorders (F32.2: T4 Rule-Out) & Serum Vitamin D in Mood Disorders (F32.2: & RBC Folate) (25(OH)D 40 – 65 ng/mL (F32.2)).
Ask our AI Specialists anything about Mood Disorders
What Is Mood Disorders?
Most people feel sad or irritable from time to time. They may say they're in a bad mood. A mood disorder is different. It affects a person's everyday emotional state. Nearly one in ten people aged 18 and older have mood disorders. These include depression and bipolar disorder (also called manic depression). Mood disorders can increase a person's risk for heart disease, diabetes, and other diseases. Treatments include medication, psychotherapy, or a combination of both. With treatment, most people with mood disorders can lead productive lives.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Mood Disorders (F32.2, Depression & Mood) reflects dopamine) signaling imbalance [Mood Disorders F32.2]. Cross-referenced with NIH MeSH (Mood Disorders), longitudinal control is benchmarked via TSH & Free in Mood Disorders (F32.2: T4 Rule-Out).
Common Symptoms & Clinical Signs
- • Presentation of Mood Disorders (F32.2): disrupted sleep architecture [Mood Disorders F32.2]
- • Secondary Mood Disorders clinical sign: slowed concentration, indecisiveness, in Mood Disorders (F32.2: and physical heaviness)
- • Symptom flares in Mood Disorders correlating with TSH & Free in Mood Disorders (F32.2: T4 Rule-Out) deviation outside TSH 0.8 – 2.5 mIU/L (F32.2)
- • Functional depression & mood impact requiring structured psychiatric history [Mood Disorders F32.2] evaluation (F32.2)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Mood Disorders Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F32.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Depression, Bipolar & Mood Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: TSH & Free in Mood Disorders (F32.2: T4 Rule-Out) | TSH 0.8 – 2.5 mIU/L (F32.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin D in Mood Disorders (F32.2: & RBC Folate) | 25(OH)D 40 – 65 ng/mL (F32.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: PHQ-9 Symptom Severity in Mood Disorders (F32.2: Score) | < 4 (clinical remission) (F32.2) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Mood Disorders
Treatment selection for Mood Disorders depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Mood Disorders)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings: What a 662-Participant Study Found The KEEPS-Cog findings suggest that for recently postmenopausal women, MHT did not alter cognition as hypothesized. PLoS medicine • 2015-06-15 • Randomized Controlled Trial | N = 662 | 93/100 | PMID 26035291 ↗ |
| Can This Approach Help? Inside the Latest Research on Cariprazine as a maintenance therapy in the prevention of mood episodes in adults Cariprazine was not superior to placebo in the prevention of relapses in this study. Bipolar disorders • 2024-08-15 • Phase III Randomized Trial | N = 148 | 88/100 | PMID 38609342 ↗ |
| Can This Approach Help? Inside the Latest Research on A common symptom geometry of mood improvement under sertraline and placebo Mapping from data-driven symptom improvement onto neural circuits revealed treatment-responsive neural profiles that may aid in optimal patient selection for future trials. Psychological medicine • 2025-07-04 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 40611472 ↗ |
| Can This Approach Help? Inside the Latest Research on Exit Interviews Examining Changes to Mood and Work/Productivity Impacts Related This study provides novel insights into women's experiences of VMS-associated impacts on mood and work/productivity, highlighting the emotional and economic burdens of VMS. The patient • 2025-11-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40650860 ↗ |
| New Insights on Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with: What a 248-Participant Study Found Brexpiprazole 1 mg daily was an appropriate starting dose and both 1 mg and 2 mg daily were effective and well tolerated as add-on treatment for Japanese MDD patients not adequately responsive to ADT. Psychiatry and clinical neurosciences • 2024-02-15 • Phase III Randomized Trial | N = 248 | 88/100 | PMID 37933521 ↗ |
Mood Disorders Patient Community & “People Like Me” Threads
Filter Mood Disorders community threads and patient logs by age, biological sex, dosage, and treatment duration.